Efficacy of Metformin in the Prevention and Management of Paclitaxel Chemotherapy-Induced Peripheral Neuropathy: A Systematic Literature Review
DOI:
https://doi.org/10.37275/bsm.v8i5.986Keywords:
Metformin, Paclitaxel, Peripheral neuropathy, Prevention, Quality of lifeAbstract
Background: Peripheral neuropathy is a common side effect of paclitaxel chemotherapy that can cause tingling, numbness, and pain in the hands and feet. Metformin, an antidiabetic drug, shows potential in preventing and managing paclitaxel chemotherapy-induced peripheral neuropathy. This review article aims to evaluate the efficacy of metformin in the prevention and management of peripheral neuropathy due to paclitaxel chemotherapy.
Methods: Electronic literature (PubMed, Scopus, Web of Science) was reviewed to find clinical studies examining the efficacy of metformin in the prevention and management of paclitaxel chemotherapy-induced peripheral neuropathy.
Results: Eight clinical studies with a total of 542 patients were evaluated. Metformin significantly reduced the risk of developing peripheral neuropathy compared with placebo (OR = 0.54; 95% CI: 0.32-0.91). Metformin significantly reduced neuropathy symptom scores compared with placebo (MD = -1.52; 95% CI: -2.43 to -0.61). Metformin significantly improved patients' quality of life compared with placebo (MD = 0.48; 95% CI: 0.17-0.79).
Conclusion: Metformin shows promising efficacy in the prevention and management of paclitaxel chemotherapy-induced peripheral neuropathy.
Authors
- Rizal Rizal1*
- 1Subspecialized Residency Training Student, Oncology Surgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Corresponding author Rizal Rizal — send2rizal@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
